131 related articles for article (PubMed ID: 35491212)
1. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM
JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
Front Immunol; 2022; 13():892331. PubMed ID: 36003404
[TBL] [Abstract][Full Text] [Related]
4. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
[TBL] [Abstract][Full Text] [Related]
7. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
8. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
[TBL] [Abstract][Full Text] [Related]
10. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M
Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863
[TBL] [Abstract][Full Text] [Related]
11. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
[TBL] [Abstract][Full Text] [Related]
14. Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
Togashi K; Hatakeyama S; Yoneyama T; Hamaya T; Narita T; Fujita N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
Int J Urol; 2022 Jul; 29(7):733-739. PubMed ID: 35362143
[TBL] [Abstract][Full Text] [Related]
15. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).
Haidar G; Agha M; Bilderback A; Lukanski A; Linstrum K; Troyan R; Rothenberger S; McMahon DK; Crandall MD; Sobolewksi MD; Nathan Enick P; Jacobs JL; Collins K; Klamar-Blain C; Macatangay BJC; Parikh UM; Heaps A; Coughenour L; Schwartz MB; Dueker JM; Silveira FP; Keebler ME; Humar A; Luketich JD; Morrell MR; Pilewski JM; McDyer JF; Pappu B; Ferris RL; Marks SM; Mahon J; Mulvey K; Hariharan S; Updike GM; Brock L; Edwards R; Beigi RH; Kip PL; Wells A; Minnier T; Angus DC; Mellors JW
Clin Infect Dis; 2022 Aug; 75(1):e630-e644. PubMed ID: 35179197
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
18. Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study.
Pertzov B; Shmueli E; Ben Zvi H; Massarweh A; Barkan T; Ness A; Shostak Y; Freidkin L; Shtraichman O; Kramer MR
Respir Res; 2022 Sep; 23(1):226. PubMed ID: 36045374
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers.
Ikezaki H; Nomura H; Shimono N
J Infect Chemother; 2022 Jun; 28(6):802-805. PubMed ID: 35288023
[TBL] [Abstract][Full Text] [Related]
20. Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients.
Fattizzo B; Bortolotti M; Rampi N; Cavallaro F; Giannotta JA; Bucelli C; Cassin R; Da Vià MC; Galassi G; Noto A; Pettine L; Rossi FG; Sciumè M; Ceriotti F; Consonni D; Barcellini W; Baldini L
Front Immunol; 2022; 13():852158. PubMed ID: 35634287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
